

## USEFULNESS/ADVANTAGES

- Since EV71 causes severe infections mostly in children, we utilized a newborn mouse model to mimic children's immunological responses.
- NPt-VP1<sub>1-100</sub> protein effectively reduced the mortality rate and improved recovery after EV71 viral infection.
- The antibodies also contributed towards reducing viral load at early stages of infection which led to successful viral clearance in the brain and spinal cord.

## MARKET POTENTIAL

NPt-VP1<sub>1-100</sub> protein is a promising candidate subunit vaccine for EV71 infection.



## INTRODUCTION/NOVELTY

The development of NPt-VP1<sub>1-100</sub>, a subunit candidate vaccine which had truncated VP1 protein of EV71 capsid protein as a C terminal extension of a truncated nucleocapsid protein of Newcastle Disease Virus. It is able to trigger significant immunity in both cell-mediated and humoral type responses.





Figure 1: Viral protection study. (a) Survival rate of newborn ICR mice after viral challenge. (b) The body weight was monitored daily after EV71 challenge. (c) Determination of anti-VP1 IgG antibodies generated in mice after immunization and viral challenge. \*,  $p < 0.0001$  versus the control group. ND indicates that the test was not done since all mice in the NPfl group died before day 10 post-challenge. (d) Detection of EV71 viral antigen in the brain and spinal cord of mice from the NPfl- and NPt-VP1<sub>1-100</sub>-immunized groups at day 5 and day 29 post-challenge. Arrows indicate positive antigen detection. Magnification = 400 $\times$ .



Project Leader : Assoc. Prof. Dr. Norazizah Shafee  
Co-Researcher : Datin Paduka Prof. Khatijah Yusoff and Mr. Ch'ng Wei Choong  
Department/Lab : Department of Microbiology, Virology Lab  
Faculty : Biotechnology and Biomolecular Sciences  
Email : nshafee@biotech.upm.edu.my  
Phone : +603-8946 6719  
Project Leader Expertise : Molecular Biology

**Research and Innovation Promotion Division**  
**Office of the Deputy Vice Chancellor**  
**(Research & Innovation)**  
T: +603-8947 1246  
F: +603-8947 1635